INTOCELL Rises on Patent Resolution, Partnership Boost with Samsung Bioepis

INTOCELL's patent dispute over its core Nexatecan3 ADC technology was resolved when Samsung Bioepis signed an exclusive license agreement with Chinese biotech Frontline Biopharma. The deal addressed patent overlap concerns that had created market uncertainty and led to Abybel Bio terminating its licensing agreement with INTOCELL in July. The resolution cleared patent risks and reinforced INTOCELL's partnership with Samsung Bioepis for developing ADC candidates.